Analysts Issue Forecasts for FOLD Q2 Earnings

Amicus Therapeutics, Inc. (NASDAQ:FOLD) – Equities researchers at Leerink Partnrs issued their Q2 2025 earnings estimates for shares of Amicus Therapeutics in a report issued on Monday, January 20th. Leerink Partnrs analyst J. Schwartz forecasts that the biopharmaceutical company will post earnings per share of ($0.01) for the quarter. The consensus estimate for Amicus Therapeutics’ current full-year earnings is ($0.04) per share. Leerink Partnrs also issued estimates for Amicus Therapeutics’ Q4 2025 earnings at $0.07 EPS and FY2025 earnings at $0.04 EPS.

Other research analysts have also issued research reports about the company. Guggenheim boosted their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Morgan Stanley restated an “equal weight” rating and set a $12.00 target price (down from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. JPMorgan Chase & Co. lifted their price target on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 12th. StockNews.com cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $21.00 target price on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Amicus Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $16.88.

Amicus Therapeutics Stock Performance

Shares of NASDAQ:FOLD opened at $9.41 on Tuesday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15. The firm’s 50 day moving average is $9.68 and its two-hundred day moving average is $10.53. Amicus Therapeutics has a 52 week low of $8.78 and a 52 week high of $14.03.

Insider Buying and Selling

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $11.46, for a total transaction of $85,950.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $10,161,054.84. The trade was a 0.84 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders sold 22,901 shares of company stock worth $259,863. Corporate insiders own 2.20% of the company’s stock.

Institutional Trading of Amicus Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. OLD Second National Bank of Aurora acquired a new position in Amicus Therapeutics in the 3rd quarter valued at approximately $26,000. Hazlett Burt & Watson Inc. boosted its position in Amicus Therapeutics by 156.9% in the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 1,569 shares in the last quarter. Blue Trust Inc. boosted its holdings in shares of Amicus Therapeutics by 1,705.4% in the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 2,831 shares in the last quarter. Arcadia Investment Management Corp MI acquired a new position in Amicus Therapeutics in the third quarter worth $32,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Amicus Therapeutics during the 3rd quarter worth about $55,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.